2025 Autumn Conference Posters

Click title to view pdf. Posters are listed in numerical order as they appear in the poster session. 

1 – Korolev – Effect of demographics on EEG/ERP biomarkers of schizophrenia: Analysis across four pharma-sponsored CNS clinical trials (Abstract)

2 – Echevarria – Impact of rater change in schizophrenia clinical trials using the PANSS (Abstract)

3 – Daniel – Comparison of percent change from baseline using 10 vs. 30 items of the PANSS in an adult, acutely exacerbated clinical trial population with schizophrenia (Abstract)

4 – Kott – The prevalence and relationship of anxiety and depression in acute schizophrenia clinical trials (Abstract)

5 – Engler – Methodological considerations and regional differences in risk-based data monitoring in global depression trials (Abstract)

6 – Rumerman – From paper to precision: Improved MADRS scoring accuracy with eCOA implementation (Abstract)

7 – Khan – A composite Rater Performance Index (RPI) to enhance rater oversight in depression clinical trials (Abstract)

8 – Roy – Ensuring data integrity through calibrated central quality reviewers (Abstract)

9 – Hewitt – COMP 005 and COMP 006: Approaches to challenges in randomized-controlled clinical trials with psychedelics (Abstract)

10 – zu Eulenburg – Precision psychiatry in MDD: Finite mixture modeling of nelivaptan response suggests distinct responder classes (Abstract)

11 – Garneni – Misclassification of treatment-resistant depression: Addressing trial eligibility by evaluating antidepressant discontinuation (Abstract)

12 – Stravoravdi – Cognitive safety assessment in a randomized, double-blind, phase 2 RSV clinical trial in adults over 60 years of age (Abstract)

13 – Harvey – Cognitive variability as a design consideration in cognitive impairment associated with schizophrenia (CIAS) treatment trials (Abstract)

14 – Snipes – Adapting bridging study methodology for prescription digital therapeutics: A case study in migraine prevention with CT-132 (Abstract)

15 – Price – A dual-table framework for rigorous definition of integrated interventions in CNS trials (Abstract)

16 – Murck – Combining digital therapeutics with neuroplasticity-inducing agents: A framework modeled on MAT (Abstract)

17 – Taptiklis – Factors influencing adherence in a remote observational study with multiple immunology and neurology disease cohorts (Abstract)

18 – Anand – Do we fully capture patient experiences? Incorporating patient and caregiver voices to define clinical meaningfulness in neurodegenerative trials (Abstract)

19 – Belleface – Assessing recruitment funnel performance: A comparative analysis of digital advertising and HCP referrals in Alzheimer’s trials (Abstract)

20 – Pironet – Clustering of medication adherence trajectories (Abstract)

21 – Gross – Retention unlocked: A tech-enabled operational monitoring and reporting framework to reduce early termination in clinical trials (Abstract)

22 – Gross – AI-enabled direct observation of participant medication adherence predicts early termination risk in clinical trials (Abstract)

23 – Mikus – Evaluating the validity of LLM-based psychological assessments: A comparative study using the Attributional Style Questionnaire (Abstract)

24 – Geraci – Leveraging ML-derived patient personas to assess functional unblinding in ketamine trials for major depressive disorder (Abstract)

25 – McLaughlin – Feasibility of an AI-administered COA using a multi-agent framework (Abstract)

26 – Bruzinski – Benchmarking commercial and open-source speech AI for speaker attribution in real-world clinical conversations (Abstract)

27 – DeBonis – Maximizing ROI in CNS trials: Using AI models to score 100% of CNS primary outcome interviews and enhance human clinical reviews (Abstract)

28 – Lagler – Towards more reliable sleep scoring in CNS trials by way of artificial intelligence (Abstract)

29 – De Lillo – Challenges of central nervous system (CNS) drug development: Evaluation of European Medicines Agency (EMA) rejections and withdrawals by human and artificial intelligence raters (Abstract)

30 – Kolar – Using large language models for endpoint oversight (Abstract)

31 – Withdrawn

32 – Aafjes – A novel method for differentiating acute suicidal ideation and intent using multimodal digital biomarkers (Abstract)

33 – Frick – A gamified digital tool for measuring anhedonia and stress reactivity in mood disorders: The losing of control task (Abstract)

34 – Field – Developing a brain-based metric of depression severity using portable brain measurement (Abstract)

35 – Voorn – A gamified digital behavioural assessment of core mechanisms underlying depressed mood and anhedonia (Abstract)

36 – Bäuerl – A digital behavioral assessment of core mechanisms underlying feelings of anxiety and stress in uncertain situations (Abstract)

37 – Tröger – Exploring a burst design to improve psychometric properties of a remote digital cognitive assessment for clinical trials in AD (Abstract)

38 – Reh – Validation of Waveband for evaluation of sleep in hypersomnia disorders (Abstract)

39 – Lutz – Developing digital cognitive biomarkers in chronic pain: An augmented reality-based assessment of prospective memory and pain interference (Abstract)

40 – Murphy – Streamlining CNS clinical research with digital endpoints – the trade-off between shorter versus smaller trial designs (Abstract)

41 – Sommer – Interpreting patient- and clinician-reported cognitive measures in schizophrenia (Abstract)

42 – Menne – Speech markers associated with self- vs. clinician-reported negative symptoms in schizophrenia: Comparing the SNS and PANSS (Abstract)

43 – Gram Sand – Beyond speech: The advantage of combining health information modalities in objective remote assessment of schizophrenia (Abstract)

44 – Tang – An automated integrative pipeline for extracting quantitative, objective speech and language features relevant to mental health (Abstract)